2,543,939 Shares in Vor Biopharma Inc. $VOR Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. bought a new position in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,543,939 shares of the company’s stock, valued at approximately $33,275,000. Vor Biopharma comprises approximately 0.9% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 26th largest holding. Frazier Life Sciences Management L.P. owned 0.24% of Vor Biopharma at the end of the most recent quarter.

Several other large investors have also bought and sold shares of VOR. China Universal Asset Management Co. Ltd. bought a new position in Vor Biopharma during the 4th quarter worth $36,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma during the 2nd quarter worth $66,000. Chung Wu Investment Group LLC bought a new position in Vor Biopharma during the 4th quarter worth $109,000. Finally, Jane Street Group LLC bought a new position in Vor Biopharma during the 1st quarter worth $140,000. 97.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company assumed coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Stock Up 1.9%

Shares of NASDAQ:VOR opened at $14.36 on Friday. Vor Biopharma Inc. has a 12-month low of $3.63 and a 12-month high of $65.80. The business’s 50 day moving average is $15.09 and its 200 day moving average is $13.90.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. Analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the transaction, the director owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. The trade was a 11.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 3,002,903 shares of company stock worth $49,412,176 over the last 90 days. 0.27% of the stock is owned by insiders.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).